Results 41 to 50 of about 5,328 (181)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG) [PDF]

, 2022
BACKGROUND: Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non-small-cell lung cancer.
Armstrong, Amy E, Desai, Ami V, et al.,, Gauvain, Karen   +3 more
core   +1 more source

Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer [PDF]

, 2022
Tyrosine kinase inhibitors (TKIs) that target the ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene have shown dramatic therapeutic effects in patients with ROS1-rearranged non-small-cell lung cancer (NSCLC).
Ajimizu, Hitomi, Aoki, Wataru, Funazo, Tomoko, Hashimoto, Kentaro, Hirai, Toyohiro, Hosoya, Kazutaka, Itotani, Ryo, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Ozasa, Hiroaki, Sakamori, Yuichi, Tsuji, Takahiro, Yamazoe, Masatoshi, Yoshida, Hironori, Yoshida, Hiroshi   +14 more
core   +1 more source

Tyrosine Kinase Inhibitors Target B Lymphocytes [PDF]

, 2023
Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body’s proteins, it leads to various autoimmune disorders.
Esnardo Upfold, Nikki Lyn, Kamyshnyi, Aleksandr, Oksenych, Valentyn, Petakh, Pavlo   +3 more
core   +1 more source

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Pharmaceuticals, 2021
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj   +1 more source

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report [PDF]

, 2023
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses.
Alberto Giuseppe Agostara, Andrea Sartore-Bianchi, Calogero Lauricella, Diego Signorelli, Elio Gregory Pizzutilo, Giovanna Marrapese, Giulio Cerea, Laura Giuseppina Giannetta, Laura Roazzi, Rebecca Romanò, Salvatore Siena, Silvio Marco Veronese, Valentina Motta   +12 more
core   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors [PDF]

, 2023
Brain metastasis; Non-small-cell lung cancer; TaletrectinibMetástasis cerebral; Cáncer de pulmón de células no pequeñas; TalerectinibMetàstasi cerebral; Càncer de pulmó de cèl·lules no petites; TaletrectinibCrizotinib and entrectinib have been approved ...
Choi, Chang-Min, FELIP, ENRIQUETA, Liu, Geoffrey, Nagasaka, Misako, Ohe, Yuichiro, Yang, Nong, Zhou, Caicun   +6 more
core   +1 more source

Characterization of exogenous αSN response genes and their relation to Parkinson’s disease using network analyses

Frontiers in Pharmacology, 2022
Despite extensive research, the molecular mechanisms underlying the toxicity of αSN in Parkinson’s disease (PD) pathology are still poorly understood.
Zahra Nayeri, Zahra Nayeri, Farhang Aliakbari, Farhang Aliakbari, Farzaneh Afzali, Soha Parsafar, Ehsan Gharib, Daniel E. Otzen, Dina Morshedi   +8 more
doaj   +1 more source

Site - and histology - independent indications of medicinal products in oncology [PDF]

, 2023
The development of drugs approved for a site and histology-independent indication is based on the identification of biological drivers that define cancer course across anatomical sites and histologies.
MIGALI, CRISTINA
core  

ROS1 in non-small-cell lung carcinoma: A narrative review

Cancer Research, Statistics, and Treatment, 2022
ROS1 rearranged non-small-cell lung cancer (NSCLC) is a distinct molecular subtype of NSCLC, accounting for 2% of cases. Typically, these are genomic rearrangements resulting in a fusion oncoprotein that causes unabated constitutive signaling.
Shrinidhi Nathany, Ullas Batra, Rashi Sachdeva, Mansi Sharma, B P Amrith, Shriya Vaidya   +5 more
doaj   +1 more source